We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Hims & Hers Stock Plunges Post Q2 Earnings Miss, Gross Margin Down
Read MoreHide Full Article
Key Takeaways
Hims & Hers posted a wider adjusted loss as gross margin contracted despite higher quarterly revenue.
HIMS revenue climbed 38.2%, driven by U.S. growth and a sharp increase in Rest of World sales.
Hims & Hers raised its 2026 revenue outlook and expects strong year-over-year growth in the third quarter.
Hims & Hers Health, Inc. (HIMS - Free Report) reported quarterly adjusted loss per share of 10 cents in second-quarter 2026, against the year-ago period’s adjusted earnings per share (EPS) of 17 cents. The metric was wider than the Zacks Consensus Estimate of loss per share of 7 cents.
GAAP loss per share for the quarter was 37 cents against the year-ago period’s EPS of 17 cents.
HIMS’ Revenues in Detail
Hims & Hers registered revenues of $753.2 million in the second quarter, up 38.2% year over year. The figure surpassed the Zacks Consensus Estimate by 9.1%.
Solid revenues from both geographic segments drove the top line.
Shares of this company lost nearly 6.8% in today’s pre-market trading.
Hims & Hers’ Geographical Results
In the second quarter of 2026, revenues in the United States increased 15.7% year over year to $621.8 million.
Rest of the World revenues grossed $131.4 million, up from the year-ago quarter’s $7.5 million.
During the reported quarter, subscribers were 2.9 million, up 18.5% year over year.
Monthly online revenue per average subscriber increased 21.1% year over year to $92 in the second quarter. Per management, the uptick was primarily driven by changes in product mix, including uptake of HIMS’ weight loss offerings.
Hims & Hers Health, Inc. Price, Consensus and EPS Surprise
In the second quarter of 2026, Hims & Hers’ gross profit increased 15.5% year over year to $480.8 million. However, the gross margin contracted 1256 basis points to 63.8%.
Marketing expenses increased 20.4% year over year to $262.2 million, while technology and development expenses jumped 45.1% year over year to $54.9 million. General and administrative expenses surged 145.8% year over year to $165.4 million, while operations and support expenses increased 43.6% year over year to $95.5 million. Operating expenses of $577.9 million increased 48.4% year over year.
Operating loss totaled $97.2 million against the year-ago quarter’s operating profit of $26.7 million.
Hims & Hers’ Financial Position
Hims & Hers exited second-quarter 2026 with cash and cash equivalents and short-term investments of $841 million compared with $750.9 million at the end of first-quarter 2026.
Cumulative net cash provided by operating activities at the end of second-quarter 2026 was $53.4 million compared with $89.9 million a year ago.
HIMS’ Outlook
Hims & Hers has provided its revenue outlook for the third quarter and raised the same for 2026.
The company projects revenues for the third quarter of 2026 in the range of $880 million to $900 million, reflecting an uptick of 47%-50% year over year. The Zacks Consensus Estimate is pegged at $778.6 million.
For the full year, HIMS now projects revenues in the range of $3.1 billion to $3.3 billion (representing growth of 32%-41% from 2025 levels), up from the prior outlook of $2.8 billion to $3 billion (representing growth of 19%-28% from 2025 levels). The Zacks Consensus Estimate is pegged at $2.91 billion.
Our Take on Hims & Hers
Hims & Hers exited the second quarter of 2026 with better-than-expected revenues. The company recorded robust improvement in the top line and geographic revenues in the quarter. The increase in subscribers and monthly online revenue per average subscriber during the quarter was encouraging.
Per management, HIMS’ geographic results were strengthened by the close of the Eucalyptus acquisition in June. Management expects its domestic business to continue accelerating through the second half of the year. The company is optimistic about the combination of this momentum with the meaningful efficiencies being generated from Hims & Hers’ investments in AI and technology. These raise our optimism about the stock.
However, Hims & Hers’ wider-than-expected loss per share and dismal bottom-line results in the quarter were disappointing. The contraction of the gross margin during the quarter does not bode well for the stock.
HIMS’ Zacks Rank and Key Picks
Hims & Hers currently carries a Zacks Rank #3 (Hold).
Some better-ranked stocks in the broader medical space that have announced quarterly results are BrightSpring Health Services, Inc. (BTSG - Free Report) , Quest Diagnostics Incorporated (DGX - Free Report) and Avantor, Inc. (AVTR - Free Report) .
BrightSpring, sporting a Zacks Rank of 1 (Strong Buy), reported second-quarter 2026 adjusted EPS of 45 cents, beating the Zacks Consensus Estimate by 21.6%. Revenues of $3.87 billion outpaced the consensus mark by 6.1%. You can see the complete list of today’s Zacks #1 Rank stocks here.
BrightSpring has a long-term estimated growth rate of 46%. BTSG’s earnings surpassed estimates in three of the trailing four quarters and missed once, the average surprise being 16.1%.
Quest Diagnostics reported second-quarter 2026 adjusted EPS of $3.12, beating the Zacks Consensus Estimate by 11%. Revenues of $3.04 billion surpassed the Zacks Consensus Estimate by 2.2%. It currently carries a Zacks Rank #2 (Buy).
Quest Diagnostics has a long-term estimated growth rate of 9.7%. DGX’s earnings surpassed estimates in each of the trailing four quarters, the average surprise being 5.8%.
Avantor reported second-quarter 2026 adjusted EPS of 21 cents, beating the Zacks Consensus Estimate by 10.5%. Revenues of $1.69 billion surpassed the Zacks Consensus Estimate by 4.2%. It currently carries a Zacks Rank #2.
Avantor has a long-term estimated growth rate of 1.6%. AVTR’s earnings surpassed estimates in three of the trailing four quarters and missed once, the average surprise being 4.3%.
View the Zacks #1 Rank List
Image: Bigstock
Hims & Hers Stock Plunges Post Q2 Earnings Miss, Gross Margin Down
Key Takeaways
Hims & Hers Health, Inc. (HIMS - Free Report) reported quarterly adjusted loss per share of 10 cents in second-quarter 2026, against the year-ago period’s adjusted earnings per share (EPS) of 17 cents. The metric was wider than the Zacks Consensus Estimate of loss per share of 7 cents.
GAAP loss per share for the quarter was 37 cents against the year-ago period’s EPS of 17 cents.
HIMS’ Revenues in Detail
Hims & Hers registered revenues of $753.2 million in the second quarter, up 38.2% year over year. The figure surpassed the Zacks Consensus Estimate by 9.1%.
Solid revenues from both geographic segments drove the top line.
Shares of this company lost nearly 6.8% in today’s pre-market trading.
Hims & Hers’ Geographical Results
In the second quarter of 2026, revenues in the United States increased 15.7% year over year to $621.8 million.
Rest of the World revenues grossed $131.4 million, up from the year-ago quarter’s $7.5 million.
During the reported quarter, subscribers were 2.9 million, up 18.5% year over year.
Monthly online revenue per average subscriber increased 21.1% year over year to $92 in the second quarter. Per management, the uptick was primarily driven by changes in product mix, including uptake of HIMS’ weight loss offerings.
Hims & Hers Health, Inc. Price, Consensus and EPS Surprise
Hims & Hers Health, Inc. price-consensus-eps-surprise-chart | Hims & Hers Health, Inc. Quote
HIMS’ Margin Analysis
In the second quarter of 2026, Hims & Hers’ gross profit increased 15.5% year over year to $480.8 million. However, the gross margin contracted 1256 basis points to 63.8%.
Marketing expenses increased 20.4% year over year to $262.2 million, while technology and development expenses jumped 45.1% year over year to $54.9 million. General and administrative expenses surged 145.8% year over year to $165.4 million, while operations and support expenses increased 43.6% year over year to $95.5 million. Operating expenses of $577.9 million increased 48.4% year over year.
Operating loss totaled $97.2 million against the year-ago quarter’s operating profit of $26.7 million.
Hims & Hers’ Financial Position
Hims & Hers exited second-quarter 2026 with cash and cash equivalents and short-term investments of $841 million compared with $750.9 million at the end of first-quarter 2026.
Cumulative net cash provided by operating activities at the end of second-quarter 2026 was $53.4 million compared with $89.9 million a year ago.
HIMS’ Outlook
Hims & Hers has provided its revenue outlook for the third quarter and raised the same for 2026.
The company projects revenues for the third quarter of 2026 in the range of $880 million to $900 million, reflecting an uptick of 47%-50% year over year. The Zacks Consensus Estimate is pegged at $778.6 million.
For the full year, HIMS now projects revenues in the range of $3.1 billion to $3.3 billion (representing growth of 32%-41% from 2025 levels), up from the prior outlook of $2.8 billion to $3 billion (representing growth of 19%-28% from 2025 levels). The Zacks Consensus Estimate is pegged at $2.91 billion.
Our Take on Hims & Hers
Hims & Hers exited the second quarter of 2026 with better-than-expected revenues. The company recorded robust improvement in the top line and geographic revenues in the quarter. The increase in subscribers and monthly online revenue per average subscriber during the quarter was encouraging.
Per management, HIMS’ geographic results were strengthened by the close of the Eucalyptus acquisition in June. Management expects its domestic business to continue accelerating through the second half of the year. The company is optimistic about the combination of this momentum with the meaningful efficiencies being generated from Hims & Hers’ investments in AI and technology. These raise our optimism about the stock.
However, Hims & Hers’ wider-than-expected loss per share and dismal bottom-line results in the quarter were disappointing. The contraction of the gross margin during the quarter does not bode well for the stock.
HIMS’ Zacks Rank and Key Picks
Hims & Hers currently carries a Zacks Rank #3 (Hold).
Some better-ranked stocks in the broader medical space that have announced quarterly results are BrightSpring Health Services, Inc. (BTSG - Free Report) , Quest Diagnostics Incorporated (DGX - Free Report) and Avantor, Inc. (AVTR - Free Report) .
BrightSpring, sporting a Zacks Rank of 1 (Strong Buy), reported second-quarter 2026 adjusted EPS of 45 cents, beating the Zacks Consensus Estimate by 21.6%. Revenues of $3.87 billion outpaced the consensus mark by 6.1%. You can see the complete list of today’s Zacks #1 Rank stocks here.
BrightSpring has a long-term estimated growth rate of 46%. BTSG’s earnings surpassed estimates in three of the trailing four quarters and missed once, the average surprise being 16.1%.
Quest Diagnostics reported second-quarter 2026 adjusted EPS of $3.12, beating the Zacks Consensus Estimate by 11%. Revenues of $3.04 billion surpassed the Zacks Consensus Estimate by 2.2%. It currently carries a Zacks Rank #2 (Buy).
Quest Diagnostics has a long-term estimated growth rate of 9.7%. DGX’s earnings surpassed estimates in each of the trailing four quarters, the average surprise being 5.8%.
Avantor reported second-quarter 2026 adjusted EPS of 21 cents, beating the Zacks Consensus Estimate by 10.5%. Revenues of $1.69 billion surpassed the Zacks Consensus Estimate by 4.2%. It currently carries a Zacks Rank #2.
Avantor has a long-term estimated growth rate of 1.6%. AVTR’s earnings surpassed estimates in three of the trailing four quarters and missed once, the average surprise being 4.3%.